Qomolangma Acquisition Corp.

2022 Q4 Form 10-Q Financial Statement

#000121390022072039 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $200.0K $60.00K $70.00K
YoY Change
Cash & Equivalents $196.5K $55.26K $73.25K
Short-Term Investments
Other Short-Term Assets $240.0K
YoY Change
Inventory
Prepaid Expenses $235.5K
Receivables
Other Receivables
Total Short-Term Assets $432.0K $60.00K $70.00K
YoY Change 179.49%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $53.96M
YoY Change
Other Assets $0.00 $220.0K $180.0K
YoY Change
Total Long-Term Assets $53.96M $218.8K $180.0K
YoY Change 40470.44%
TOTAL ASSETS
Total Short-Term Assets $432.0K $60.00K $70.00K
Total Long-Term Assets $53.96M $218.8K $180.0K
Total Assets $54.39M $278.8K $250.0K
YoY Change 18814.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $124.6K $65.00K $40.00K
YoY Change 91.69%
Deferred Revenue
YoY Change
Short-Term Debt $160.0K $200.0K $200.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $371.2K $265.0K $240.0K
YoY Change 39.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.110M
YoY Change
Total Long-Term Liabilities $2.110M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $371.2K $265.0K $240.0K
Total Long-Term Liabilities $2.110M $0.00 $0.00
Total Liabilities $2.517M $270.0K $240.0K
YoY Change 844.29%
SHAREHOLDERS EQUITY
Retained Earnings $130.9K -$11.21K
YoY Change -3426.96%
Common Stock $166.00 $144.00
YoY Change 15.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.045M $13.79K $8.780K
YoY Change
Total Liabilities & Shareholders Equity $54.39M $278.8K $250.0K
YoY Change 18814.22%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Type
DocumentType
10-Q
CY2022Q3 us-gaap Cash
Cash
55264 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41518
dei Entity Registrant Name
EntityRegistrantName
Qomolangma Acquisition Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3733656
dei Entity Address Address Line1
EntityAddressAddressLine1
1178 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
791-7587
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
QOMO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6587623 shares
CY2021Q4 us-gaap Cash
Cash
154565 usd
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
223530 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
133000 usd
CY2022Q3 us-gaap Assets
Assets
278794 usd
CY2021Q4 us-gaap Assets
Assets
287565 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1500 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65000 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
200000 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
200000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
265000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
266500 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
16000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
16000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1437500 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1437500 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1437500 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1437500 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
144 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24856 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24856 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11206 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3935 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13794 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21065 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278794 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287565 usd
CY2022Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
122 usd
CY2021Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
3635 usd
us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
7271 usd
us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
3635 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5136 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
5014 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3635 usd
us-gaap Net Income Loss
NetIncomeLoss
-7271 usd
us-gaap Net Income Loss
NetIncomeLoss
-3635 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21065 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7318 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13747 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4967 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
8780 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
5014 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13794 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3635 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21365 usd
us-gaap Net Income Loss
NetIncomeLoss
-7271 usd
us-gaap Net Income Loss
NetIncomeLoss
-3635 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7271 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3635 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
200000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000 usd
qomo Payment Of Offering Costs
PaymentOfOfferingCosts
90530 usd
qomo Reimbursement Of Formation Costs Paid By Related Party
ReimbursementOfFormationCostsPaidByRelatedParty
1500 usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
1200 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-92030 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
226200 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-99301 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
222565 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154565 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55264 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
222565 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
200000 usd
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.01 pure
qomo Deferred Offering Costs In Accrued Expenses
DeferredOfferingCostsInAccruedExpenses
65000 usd
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.15
qomo Maturity Days
MaturityDays
P185Y
qomo Trust Account Description
TrustAccountDescription
Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test.
qomo Aggregate Fair Market Percentage
AggregateFairMarketPercentage
0.80 pure
qomo Financing Receivable Non Accrual To Outstanding Percent
FinancingReceivableNonAccrualToOutstandingPercent
0.50 pure
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.15
us-gaap Asset Acquisition Consideration Transferred Other Assets
AssetAcquisitionConsiderationTransferredOtherAssets
5000001 usd
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1 pure
CY2022Q3 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
10.15
CY2022Q3 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
10.15
CY2022Q3 qomo Reductions Per Share
ReductionsPerShare
10.15
CY2022Q3 us-gaap Cash
Cash
55264 usd
qomo Working Capital
WorkingCapital
209736 usd
us-gaap Sponsor Fees
SponsorFees
25000 usd
qomo Public Shares Sold
PublicSharesSold
5273000 shares
CY2022Q3 qomo Excise Tax Percentage
ExciseTaxPercentage
0.01 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited condensed financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
55264 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
154565 usd
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
223530 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
133000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5000000 shares
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10
CY2022Q4 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
50000000 usd
CY2022Q4 us-gaap Option Indexed To Issuers Equity Shares
OptionIndexedToIssuersEquityShares
750000 shares
CY2022Q4 us-gaap Option Indexed To Issuers Equity Shares
OptionIndexedToIssuersEquityShares
273000 shares
CY2022Q4 qomo Generating Gross Proceeds
GeneratingGrossProceeds
2730000 usd
qomo Initial Public Offering Description
InitialPublicOfferingDescription
Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
260500 shares
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2605000 usd
us-gaap Partners Capital Account Units Sold In Private Placement
PartnersCapitalAccountUnitsSoldInPrivatePlacement
8873 shares
qomo Generating Gross Proceeds
GeneratingGrossProceeds
88725 usd
qomo Private Placement Description
PrivatePlacementDescription
Each Private Unit consists of one share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business Combination.
CY2021 qomo Outstanding Promissory Note
OutstandingPromissoryNote
200000 usd
qomo Initial Stockholders Percentage
InitialStockholdersPercentage
0.20 pure
qomo Outstanding Promissory Note
OutstandingPromissoryNote
200000 usd
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
68250 shares
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1437500 shares
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
25000 usd
CY2022Q3 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
1437500 shares
CY2022Q3 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
1437500 shares
CY2022Q3 qomo Subject To Forfeiture Shares
SubjectToForfeitureShares
187500 shares
qomo Issued And Outstanding Shares Percentage
IssuedAndOutstandingSharesPercentage
0.20 pure
CY2022Q4 qomo Subject To Forfeiture Shares
SubjectToForfeitureShares
68250 shares
qomo Founder Shares Percentage
FounderSharesPercentage
0.50 pure
CY2021Q3 qomo Aggregate Amount
AggregateAmount
200000 usd
CY2022Q3 qomo Repaid Outstanding Balance
RepaidOutstandingBalance
200000 usd
us-gaap Payments For Rent
PaymentsForRent
10000 usd
qomo Additional Units To Underwriters
AdditionalUnitsToUnderwriters
750000 shares
qomo Purchase Units
PurchaseUnits
273000 shares
qomo Deferred Underwriting Discount Percentage
DeferredUnderwritingDiscountPercentage
0.0175 pure
qomo Deferred Fee Percentage
DeferredFeePercentage
0.04 pure
qomo Gross Proceeds
GrossProceeds
2000000 usd
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
75000 shares
CY2022Q3 us-gaap Shares Issued
SharesIssued
16000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the common stock are entitled to one vote for each share.
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1437500 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1437500 shares
CY2022Q3 qomo Subject To Forfeiture Shares
SubjectToForfeitureShares
187500 shares
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
usd
qomo Redeem The Outstanding Warrants
RedeemTheOutstandingWarrants
●in whole and not in part; ●at a price of $0.01 per warrant;  ●upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period;  ●if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the warrant holders. 
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
usd
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
qomo Payment Of Offering Costs
PaymentOfOfferingCosts
usd
qomo Reimbursement Of Formation Costs Paid By Related Party
ReimbursementOfFormationCostsPaidByRelatedParty
usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
qomo Deferred Offering Costs In Accrued Expenses
DeferredOfferingCostsInAccruedExpenses
usd
us-gaap Discontinued Operation Provision For Loss Gain On Disposal Before Income Tax
DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001894210

Files In Submission

Name View Source Status
qomo-20220930_cal.xml Edgar Link unprocessable
0001213900-22-072039-index-headers.html Edgar Link pending
0001213900-22-072039-index.html Edgar Link pending
0001213900-22-072039.txt Edgar Link pending
0001213900-22-072039-xbrl.zip Edgar Link pending
f10q0922ex31-1_qomolangmaacq.htm Edgar Link pending
f10q0922ex31-2_qomolangmaacq.htm Edgar Link pending
f10q0922ex32-1_qomolangmaacq.htm Edgar Link pending
f10q0922ex32-2_qomolangmaacq.htm Edgar Link pending
f10q0922_qomolangmaacq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qomo-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
qomo-20220930_def.xml Edgar Link unprocessable
qomo-20220930_lab.xml Edgar Link unprocessable
qomo-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0922_qomolangmaacq_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending